Clinical trial · Interventional
Web-Base App To Improve Aromatase Inhibitor Adherence
Use of an Innovative Mobile Health Application to Improve Health Outcomes for Breast Cancer Patients
NCT02957526CI-TRIAL-00033853AETAPPcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study will be to test the use of a web-based mobile application (app) initiated at the time of the initial prescription to an aromatase inhibitor to improve communication and management of treatment-related adverse symptoms among patients with hormone-receptor positive breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasm Female | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clinical Alerts | Behavioral | — | UNRESOLVED |
| Prompts to report symptoms via study app | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- App
- description
- The web-based app will be used to ask participants about their aromatase inhibitor use in the previous 7 days and ask about treatment-related adverse symptoms, or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
- interventionNames
- Behavioral: Prompts to report symptoms via study app
- Behavioral: Clinical Alerts
- type
- ACTIVE_COMPARATOR
- label
- Usual Care
- description
- Participants will have access to the web-based app, but will not receive reminders. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult female patients (age≥18) 2. Diagnosed with early stage (I-III) HR+ breast cancer 3. New prescription for an aromatase inhibitor 4. Have a mobile device with a data plan or a home computer with Internet 5. Have a valid email address 6. Willing to complete brief weekly symptom reports on the app Exclusion Criteria: 1. Unable to communicate in English 2. Patients with prior use of adjuvant endocrine therapy will also be excluded 3. Patients concurrently undergoing surgery, chemotherapy or radiation will also be excluded 4. Current diagnosis of rheumatoid arthritis 5. Chronic daily narcotic usage
References
Publications (1)
- DERIVEDGraetz I, McKillop CN, Stepanski E, Vidal GA, Anderson JN, Schwartzberg LS. Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial. J Cancer Surviv. 2018 Aug;12(4):431-440. doi: 10.1007/s11764-018-0682-z. Epub 2018 Feb 28. PMID 29492753